Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I-GRAINE study.
Anti-CGRP mAbs
Discontinuation
Disease-modifier
Migraine
Multiple treatments
Treatment
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
12 Feb 2024
12 Feb 2024
Historique:
received:
27
12
2023
accepted:
13
01
2024
revised:
06
01
2024
medline:
12
2
2024
pubmed:
12
2
2024
entrez:
11
2
2024
Statut:
aheadofprint
Résumé
While a single 12-month treatment cycle (TrC) with anti-CGRP mAbs is not disease-modifying for most patients, there is limited understanding of the effects of multiple TrCs on migraine course. We evaluated whether a second TrC might modify the migraine course by comparing the occurrence of migraine relapse after discontinuation of the second TrC to that following the cessation of the first TrC. In a real-life, multicenter, prospective study we considered all consecutive patients diagnosed with high-frequency episodic migraine (HFEM) or chronic migraine (CM) with > 3 treatment failures and treated with any anti-CGRP mAbs for ≥ 2 consecutive 12-month TrCs who were responders at week 12. The primary endpoint was the change in monthly migraine days (MMD) for HFEM or monthly headache days (MHD) for CM at the first month of treatment discontinuation after the second TrC (D2) compared to the first TrC (D1). Secondary endpoints included variations in monthly analgesic medications (MAM), Numeric Rating Scale (NRS), and Headache Impact Test (HIT-6) scores, ≥ 50%, ≥ 75%, and 100% response rates, and relapse from episodic migraine to CM and from no-medication overuse (MO) to MO at D2 vs. D1. One-hundred-seventy-eight patients completed two 12-month TrCs with anti-CGRP mAbs. At D2, patients experienced a significant reduction in MMD (- 0.6, p = 0.028), MHD (- 2.6, p < 0.001), monthly analgesic medications (- 2.0, p < 0.001), and HIT-6 score (- 2.2, p < 0.001) compared to D1, indicating improved effectiveness. The ≥ 50% response rate at weeks 45-48 during the first TrC was 95.5%, while at weeks 45-48 of the second TrC was 99.4%. Corresponding rates at D1 was 20.2% whereas at D2 was 51.6% (p < 0.0001). No statistical difference emerged in ≥ 75% and 100% responders. The relapse rate from episodic migraine to CM at D2 was lower than at D1 (12.3% vs 30.4%; p = 0.0002) Fewer patients experienced relapse from no-MO to MO at D2 compared to D1 (29.5% vs 68.7%; p = 0.00001). A second TrC with anti-CGRP mAbs demonstrated clinical improvements compared to the first one, as indicated by a milder migraine relapse at D2 compared to D1. Multiple TrCs with anti-CGRP mAbs could progressively modify migraine evolution by reducing CGRP-dependent neuroinflammatory nociceptive inputs to the brain.
Identifiants
pubmed: 38342785
doi: 10.1007/s00415-024-12192-9
pii: 10.1007/s00415-024-12192-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Migraine AM (2020) N Engl J Med 383(19):1866–1876
Ashina M, Buse DC, Ashina H et al (2021) Migraine: integrated approaches to clinical management and emerging treatments. Lancet 397(10283):1505–1518
doi: 10.1016/S0140-6736(20)32342-4
pubmed: 33773612
Rattanawong W, Rapoport A, Srikiatkhachorn A (2022) Neurobiology of migraine progression. Neurobiol. Pain 9(12):100094. https://doi.org/10.1016/j.ynpai.2022.100094
doi: 10.1016/j.ynpai.2022.100094
Hepp Z, Bloudek LM, Varon SF (2014) Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm 20(1):22–33
pubmed: 24372457
Sacco S, Amin FM, Ashina M et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain 23(1):67. https://doi.org/10.1186/s10194-022-01431-x
doi: 10.1186/s10194-022-01431-x
pubmed: 35690723
pmcid: 9188162
Guerzoni S, Baraldi C, Pensato U, Favoni V, Lo Castro F, Cainazzo MM, Cevoli S, Pani L (2022) Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data. Neurol Sci 43(6):3823–3830. https://doi.org/10.1007/s10072-022-05870-x . (Epub 2022 Jan 11)
doi: 10.1007/s10072-022-05870-x
pubmed: 35015202
Schiano di Cola F, Caratozzolo S, Venturelli E, Balducci U, Sidoti V, Pari E, Costanzi C, di Summa A, Sixt GJ, D’Adda E, Liberini P, Rao R, Padovani A (2021) Erenumab discontinuation after 12-month treatment: a multicentric observational real-life study. Neurol Clin Pract. 11(6):e834–e839. https://doi.org/10.1212/CPJ.0000000000001112
doi: 10.1212/CPJ.0000000000001112
pubmed: 34992966
pmcid: 8723927
Vernieri F, Brunelli N, Messina R, Costa CM, Colombo B, Torelli P, Quintana S, Cevoli S, Favoni V, d’Onofrio F, Egeo G, Rao R, Filippi M, Barbanti P, Altamura C (2021) Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. J Headache Pain 22(1):154. https://doi.org/10.1186/s10194-021-01363-y
doi: 10.1186/s10194-021-01363-y
pubmed: 34922444
pmcid: 8903705
Raffaelli B, Terhart M, Overeem LH, Mecklenburg J, Neeb L, Steinicke M, Reuter U (2022) Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. Cephalalgia 42(4–5):326–334. https://doi.org/10.1177/03331024211046617 . (Epub 2021 Sep 27)
doi: 10.1177/03331024211046617
pubmed: 34579559
Gantenbein AR, Agosti R, Gobbi C, Flügel D, Schankin CJ, Viceic D, Zecca C, Pohl H (2021) Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study. Cephalalgia 41(11–12):1181–1186. https://doi.org/10.1177/03331024211014616 . (Epub 2021 May 17)
doi: 10.1177/03331024211014616
pubmed: 34000847
pmcid: 8504406
De Matteis E, Affaitati G, Frattale I, Caponnetto V, Pistoia F, Giamberardino MA, Sacco S, Ornello R (2021) Early outcomes of migraine after erenumab discontinuation: data from a real-life setting. Neurol Sci 42(8):3297–3303. https://doi.org/10.1007/s10072-020-05022-z . (Epub 2021 Jan 2)
doi: 10.1007/s10072-020-05022-z
pubmed: 33389227
Raffaelli B, Terhart M, Mecklenburg J, Neeb L, Overeem LH, Siebert A, Steinicke M, Reuter U (2022) Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience. J Headache Pain 23(1):40. https://doi.org/10.1186/s10194-022-01417-9
doi: 10.1186/s10194-022-01417-9
pubmed: 35350990
pmcid: 8966337
Vernieri F, Brunelli N, Guerzoni S, Iannone LF, Baraldi C, Rao R, Schiano di Cola F, Ornello R, Cevoli S, Lovati C, Albanese M, Perrotta A, Cetta I, Rossi SS, Taranta V, Filippi M, Geppetti P, Sacco S, Altamura C (2023) Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study. J Neurol 270(11):5436–5448. https://doi.org/10.1007/s00415-023-11872-2 . (Epub 2023 Jul 19.PMID: 37468621)
doi: 10.1007/s00415-023-11872-2
pubmed: 37468621
Angus-Leppan H, Sperling MR, Villanueva V (2023) Antiseizure medications (antiepileptic drugs) in adults: starting, monitoring and stopping. J Neurol 270(1):573–581
doi: 10.1007/s00415-022-11378-3
pubmed: 36153467
Bandelow B, Michaelis S, Wedekind D (2017) Treatment of anxiety disorders. Dialogues Clin Neurosci 19(2):93–107
doi: 10.31887/DCNS.2017.19.2/bbandelow
pubmed: 28867934
pmcid: 5573566
Gazzetta Ufficiale della Repubblica Italiana. Serie Generale n; 2020. Accessed January 17, 2023. gazzettaufficiale.it/gazzetta/serie_generale/caricaDettaglio? Data Pubblicazione Gazzetta=2020–07–21&numeroGazzetta=182.
Labastida-Ramírez A, Caronna E, Gollion C, Stanyer E, Dapkute A, Braniste D, Naghshineh H, Meksa L, Chkhitunidze N, Gudadze T, Pozo-Rosich P, Burstein R, Hoffmann J (2023) Mode and site of action of therapies targeting CGRP signaling. J Headache Pain 24(1):125
doi: 10.1186/s10194-023-01644-8
pubmed: 37691118
pmcid: 10494408
Barbanti P, Aurilia C, Egeo G, Proietti S, D'Onofrio F, Torelli P, Aguggia M, Bertuzzo D, Finocchi C, Trimboli M, Cevoli S, Fiorentini G, Orlando B, Zucco M, Di Clemente L, Cetta I, Colombo1 B, Bandettini di Poggio ML, Favoni V, Grazzi L, Salerno A, Carnevale A, Robotti M, Frediani F, Altamura C, Filippi M, Vernieri F, Bonassi S, for the Italian Migraine Registry study group (2024) Ultra-late response (>24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study. J Neurol. https://doi.org/10.1007/s00415-023-12103-4
Ferroni P, Palmirotta R, Egeo G, Aurilia C, Valente MG, Spila A, Pierallini A, Barbanti P, Guadagni F (2022) Association of LTA and SOD gene polymorphisms with cerebral white matter hyperintensities in migraine patients. Int J Mol Sci 23(22):13781. https://doi.org/10.3390/ijms232213781
doi: 10.3390/ijms232213781
pubmed: 36430258
pmcid: 9695025
Barbanti P, Aurilia C, Egeo G, Torelli P, Proietti S, Cevoli S, Bonassi S, Italian Migraine Registry study group (2023) Late response to Anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective observational study. Neurology 101(11):482–488
doi: 10.1212/WNL.0000000000207292
pubmed: 37072224
Szabo E, Ashina S, Melo-Carrillo A, Bolo NR, Borsook D, Burstein R (2023) Peripherally acting anti-CGRP monoclonal antibodies alter cortical gray matter thickness in migraine patients: a prospective cohort study. Neuroimage Clin 40:103531. https://doi.org/10.1016/j.nicl.2023.103531 . (Epub 2023 Oct 14)
doi: 10.1016/j.nicl.2023.103531
pubmed: 37866119
pmcid: 10623369